Treace Medical Concepts

TMCI

Market cap $272M

SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Treace Medical Concepts, Inc. (NASDAQ: TMCI) against certain of its officers and directors for alleged breaches of fiduciary duty.

New portfolio addition to drive further penetration into incremental procedures throughout the foot and ankle; strengthens Treace's comprehensive suite of technologies for its growing customer base New portfolio addition to drive further penetration into incremental procedures throughout the foot and ankle; strengthens Treace's comprehensive suite of technologies for its growing customer base

PONTE VEDRA, Fla., June 11, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced it will present at the Sidoti Small Cap Conference, Thursday, June 18, 2026, beginning at approximately 1:45 pm ET.

SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Treace Medical Concepts, Inc. (NASDAQ: TMCI). The investigation focuses on Treace's executive officers and whether investor losses may be recovered under federal securities laws.

Treace Medical Concepts NASDAQ: TMCI reaffirmed its full-year 2026 revenue outlook after reporting a first-quarter revenue decline, as management said new product adoption is helping drive procedure volume momentum despite pricing and mix headwinds.

Treace Medical Concepts, Inc. (TMCI) Q1 2026 Earnings Call Transcript

Treace Medical Concepts (TMCI) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.25 per share a year ago.

PONTE VEDRA, Fla., May 08, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today reported financial results for the first quarter ended March 31, 2026.

PONTE VEDRA, Fla., April 24, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the first quarter 2026 before the start of trading on Friday, May 8, 2026. Company management will host a conference call to discuss financial results beginning at 8:00 am ET.

New portfolio addition taps into incremental procedures throughout the foot and ankle; strengthens Treace's comprehensive suite of technologies for its growing customer base New portfolio addition taps into incremental procedures throughout the foot and ankle; strengthens Treace's comprehensive suite of technologies for its growing customer base